Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing–remitting multiple sclerosis (RRMS)

Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis

(2012) Robert J. Fox et al.   NEW ENGLAND JOURNAL OF MEDICINE

Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

(2012) Ralf Gold et al.   NEW ENGLAND JOURNAL OF MEDICINE

Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway

(2011) Ralf A. Linker et al.   BRAIN

Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial

(2011) Giancarlo Comi et al.   LANCET NEUROLOGY

Circadian cortisol, depressive symptoms and neurological impairment in early multiple sclerosis

(2011) S. Kern et al.   PSYCHONEUROENDOCRINOLOGY

The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability

(2010) Antonio Scalfari et al.   BRAIN

Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1β, TNF-α and IL-6 in an in-vitro model of brain inflammation

(2010) Henrik Wilms et al.   Journal of Neuroinflammation

Cognitive and behavioural correlates of different domains of psychological adjustment in early-stage multiple sclerosis

(2010) Laura Dennison et al.   JOURNAL OF PSYCHOSOMATIC RESEARCH

Early cognitive impairment in multiple sclerosis predicts disability outcome several years later

(2010) Mathilde Deloire et al.   Multiple Sclerosis Journal

MR spectroscopy (MRS) and magnetisation transfer imaging (MTI), lesion load and clinical scores in early relapsing remitting multiple sclerosis: a combined cross-sectional and longitudinal study

(2009) J. Bellmann-Strobl et al.   EUROPEAN RADIOLOGY

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial

(2009) G Comi et al.   LANCET

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial

(2009) Ludwig Kappos et al.   LANCET NEUROLOGY

Efficacy of intramuscular interferon beta-1a in patients with clinically isolated syndrome: analysis of subgroups based on new risk criteria

(2009) P O’Connor et al.   Multiple Sclerosis Journal

Physical activity, disability, and mood in the early stage of multiple sclerosis

(2009) Yoojin Suh et al.   Disability and Health Journal

Multiple sclerosis

(2008) Alastair Compston et al.   LANCET

Multimodal evoked potentials measure and predict disability progression in early relapsing–remitting multiple sclerosis

(2008) P Jung et al.   Multiple Sclerosis Journal